Norman Jaffe, MD
Cardiovascular Disease · Oswego, NYNPI 1386630549
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $178,246 of the $195,221 with a category attached, or 91.3%. 20 manufacturers reported payments, led by Boehringer Ingelheim at 37.2% of the total. Reporting peaked in 2019 at $65,999 and has fallen 78.1% since, to $14,475 in 2023. Among cardiovascular disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 326 payments — averaging $598.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$73K
- Lilly USA, LLC$49K
- Amarin Pharma, Inc.$24K
- Johnson & Johnson$18K
- Amgen$12K
- Boston Scientific$12K
- plus $9K from 14 others
What the payments were for
- Consulting fees$1,3551%
- Speaking & faculty fees$178,24691%
- Travel & lodging$11,8426%
- Food & beverage$3,7782%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 93 | $72,533 |
| Lilly USA, LLC | 97 | $48,741 |
| Amarin Pharma, Inc. | 38 | $24,373 |
| Johnson & Johnson | 23 | $17,979 |
| Amgen | 23 | $11,554 |
| Boston Scientific | 21 | $11,519 |
| Novartis | 12 | $6,886 |
| ZOLL Medical Corporation | 1 | $335 |
| Vifor (international) Ltd. | 1 | $325 |
| BD | 1 | $320 |
| Medtronic | 3 | $138 |
| AstraZeneca | 2 | $137 |
| Sanofi | 1 | $125 |
| Bayer | 2 | $121 |
| Gilead | 3 | $43 |
| Vifor Pharma, Inc. | 1 | $25 |
| Novo Nordisk | 1 | $20 |
| Abiomed | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$195,221 in reported general payments places this provider in the 95th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Oswego
- Roger HajjarNew York$5.2M
- Szilard VorosStony Brook$3.7M
- Gregg StoneNew York$2M
- Augustin DelagoAlbany$1.8M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Luigi di BiaseBronx$978K
- Vijay IyerAmherst$855K
- Megha PrasadNew York$813K
- Ronald DagostinoLake Success$782K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.